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Background. e ATP-binding cassette, subfamily D, member 1 (ABCD1) protein is a peroxisomal half-transporter that allows for 
very long chain fatty acid (VLCFA) degradation. Pathogenic variants of ABCD1 cause VLCFAs to build up in various tissues and 
bodily fluids, resulting in a disorder called X-linked adrenoleukodystrophy (X-ALD). is disorder is most commonly marked 
by adrenocortical insufficiency and high VLCFA concentration, and has varying levels of neurological involvement depending 
on phenotype. For example, the Addison-only form of X-ALD has no neurological impact, while the cerebral form of X-ALD 
oen causes severe sensory loss, motor function impairment, cognitive decline, and death. Methods. A newly characterized and 
suspected pathogenic variant in ABCD1 was analyzed using our protein informatics platform (PIP). Personalized protein-level 
molecular studies were completed on genetic testing data, complementing the analysis and clinical study. Results. A case of adult 
onset adrenomyeloneuropathy (AMN) and a novel ABCD1 variant are presented. e unique ABCD1 protein is discussed, and 
the proband’s case is compared to existing reports of AMN. Conclusions. Data fusion from multiple sources was combined in a 
comprehensive approach yielding an enriched assessment of the patient’s disease and prognosis. Molecular modeling was performed 
on the variant to better characterize its clinical significance and confirm pathogenicity.
1. Introduction
e ATP-binding cassette, subfamily D, member 1 (ABCD1) 
protein is part of the ATP-binding cassette transporter super-
family, which consists of transmembrane proteins responsible 
for passing lipids, metabolites, and other molecules between 
cells or intracellular structures. It is encoded by ABCD1, a gene 
located at Xq28 [OMIM#300371]. ABCD1 is a peroxisomal 
half-transporter that imports very long chain fatty acids 
(VLCFA) into the peroxisome by binding ATP. Dysfunctional 
ABCD1 is unable to move VLCFAs to the peroxisome to be 
degraded, resulting in VLCFA accumulation in body fluids 
and tissues [1]. is abnormal level of VLCFAs serves as a 
characteristic biomarker of X-linked adrenoleukodystrophy 
(X-ALD), the most common peroxisomal disorder [2]. X-ALD 
is a genetic condition primarily associated with demyelination, 
neurodegeneration, and adrenocortical insufficiency [3]. Over 
800 variants have been reported within the ABCD1 gene [ALD 
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Mutation Database]. Despite this, clear genotype–phenotype 
correlations have not been observed [4].
Hemizygous males typically exhibit the most significant 
symptoms, while heterozygous females oen develop a lesser 
degree of disability later in life [2]. e three classic pheno-
types are Addison disease-only, adrenomyeloneuropathy 
(AMN), and cerebral ALD. Individuals with the Addison dis-
ease-only form usually present with adrenocortical insuffi-
ciency between 2 and 7 years old. Neurologic degeneration is 
not present initially, but it oen develops as the individual ages 
[5]. AMN typically onsets in the third to fourth decade of life 
and primarily affects the spinal cord [3]. e presenting clin-
ical feature is oen progressive leg stiffness and weakness. 
Adrenal insufficiency is found in roughly 2/3 of AMN patients, 
and cerebral changes affect around half of them [3]. Cerebral 
ALD is the most severe phenotype, where cerebral demyeli-
nation causes rapid decline in hearing, sight, motor function, 
and cognition [5]. Most commonly found in children or ado-
lescents, this variant of X-ALD oen results in death within 
2–4 years of symptom presentation [2].
is report details the history of a proband diagnosed in 
his thirties with AMN. Molecular analysis of the ABCD1 gene 
identified a variant of uncertain significance within this indi-
vidual. Interestingly, this variant has been reported pathogenic 
in the ALD Mutation Database, but information regarding the 
clinical case was not published. Our proband’s clinical case is 
included to better support the pathogenicity of this ABCD1 
variant. Protein informatics platform (PIP) was utilized for 
comprehensive molecular modeling to further characterize 
the significance of this variant and clarify to the proband’s 
diagnosis.
2. Case Study (Clinical Description)
e proband was a 31-year-old male who presented for eval-
uation of a progressive neurologic condition. Symptoms of 
this condition first appeared 2 years ago when the proband 
began to trip increasingly oen. He would later experience 
generalized muscle weakness and stiffness, along with further 
gait dysfunction. To combat this, the proband had used a roll-
ing walker to aid in ambulation for the past 7 months. He had 
also developed urinary incontinence. Furthermore, he 
reported brain fog, memory loss, attention deficits, anxiety, 
and fatigue. Basic mental tasks took longer to complete as a 
result. Per the proband, alcohol use exacerbated these deficits. 
Finally, the proband lost 20 pounds since the onset of his con-
dition and was unable to regain weight despite concerted 
efforts to do so. is weight loss was partially due to symptoms 
of nausea and vomiting, which were most common in the 
morning.
During physical examination, the proband was unable to 
rise from a sitting position without the use of his hands. Mild 
ataxic dysarthria was identified. Visual fixation tests revealed 
infrequent square wave jerks. Smooth pursuits were saccadic, 
and he demonstrated slow, full saccades both vertically and 
horizontally. Stretch reflexes were pathologically brisk in the 
upper extremities. e proband also had pathologically brisk 
mitotic stretch reflexes in the lower extremities, including sus-
tained clonus at the ankles. Moderately impaired propriocep-
tion of the great toes was present. Mild upper motor 
neuron-distribution weakness was seen in the lower extrem-
ities with sparing of the iliopsoas. Heel-to-shin testing revealed 
dyssynergia. While ambulating, the proband looked at his feet 
and moved with a reduced stride. His knees hyperextended, 
he tended to toe walk, and occasionally he slid his feet. 
Romberg sign was present. While standing, tremulous move-
ments were present in his legs—predominantly in the quadri-
ceps. e proband turned 360 degrees over 3 trials, which 
required 9 to 15 steps per turn. His postural reflexes were 
abnormal, and the “Pull” test was −3.
MRI of the brain was normal, and MRI of the cervical 
spine revealed findings suggestive of mild, diffuse spinal cord 
atrophy. ere was no evidence for subacute combined degen-
eration or other acquired spinal cord disease (Figure 1). He 
had been treated for Lyme disease, as his Lyme IgM titers were 
positive, but no significant improvement had been recorded. 
His cerebrospinal fluid was described as acellular. Evaluation 
of HIV, HTLV1, hepatitis C, hepatitis B, and cytomegalovirus 
returned negative. Family history of similar symptoms could 
not be established, as the proband’s knowledge of their medical 
histories was limited (Figure 2).
e proband’s peroxisomal fatty acid profile was 
obtained aer the previous tests and imaging. Abnormal 
concentrations of C26 : 0, C24/C22, and C26/C22 were 
present, which suggested hemizygosity for X-linked 
adrenomyeloneuropathy. Adrenocorticotropic hormone 
measured 528 pg/mL (RR: 7.2–63). Sequencing and deletion/
duplication analysis of the ABCD1 gene was then completed. 
e proband was hemizygous for a variant of uncertain 
significance in ABCD1, c.1599G>T (p.Lys533Asn). is 
variant was not present in the ExAC online database, though 
it was listed as pathogenic in the ALD Mutation Database. 
Two similar variants, c.1596A>G (p.Lys533Glu) and 
c.1598A>G (p.Lys533Arg), have also been reported 
previously as clinically significant [6, 7].
Figure 1: MRI of cervical spine. MRI of the cervical spine revealed 
findings suggestive of mild diffuse spinal cord atrophy.
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3. Methods
3.1. Structural Modeling. e sequence of human ATP-
binding cassette subfamily D member 1 (known as ABCD1) 
is likely a transporter protein, which has a nucleotide-binding 
region with a fold that can act as an ATP-binding subunit 
with ATPase activity. It is known that correct dimerization is 
required to form an active transporter. ABCD1 is a member 
of the ALD subfamily that takes part in peroxisomal fatty acid 
import into organelles. ese peroxisomal ABC transporters 
are “half transporters,” meaning that they require a partner 
half transporter molecule—the functional form is always 
homodimeric or heterodimeric. ABCD1 is assumed to be 
the key for peroxisomal transport or catabolism of very long 
chain fatty acids. ABCD1 is known to interact with PEX19, 
and is encoded by the ABCD1 gene, which was taken from 
the NCBI Reference Accession Sequence: NP_000024: version 
NP_000024.2, which is encoded for the amino acid sequence; 
and was used for computer assisted modeling. Monte Carlo 
simulations were performed on the mutant to allow local 
regional changes for full-length 745 amino acids.
e X-ray refinement for Monte Carlo was built using the 
YASARA SSP/PSSM Method [8–13]. e structure was relaxed 
to the YASARA/Amber force field using knowledge-based 
potentials within YASARA. e side chains and rotamers were 
adjusted with knowledge-based potentials, simulated anneal-
ing with explicit solvent, and small equilibration simulations 
using YASARA’s refinement protocol [14]. e entire full-
length structure was modeled, filling in any gaps or unresolved 
portions from the X-ray.
Refinement of the finalized models was completed using 
either the Schrodinger’s LC-MOD Monte Carlo-based module 
or the NAMD2 protocols. ese refinements started with 
YASARA generated initial refinement and variant [8–10, 12]. 
e superposition and subsequent refinement of the 
overlapping regions yields a complete model for the ABCD1. 
e final structures were subjected to energy optimization 
with PR conjugate gradient with an R-dependent dielectric.
Atom consistency was checked for all 745 amino acids 
(12,201 atoms) of the full-length wild-type model (WT) and 
745 amino acids (12,221 atoms) for the variant, verifying cor-
rectness of chain name, dihedrals, angles, torsions, nonbonds, 
electrostatics, atom-typing, and parameters. A dimer model 
is predicted, which consists of 24,402 atoms including cofac-
tors and ions. Each model was exported to the following for-
mats: Maestro (MAE), and YASARA (PDB). Model 
manipulation was done with Maestro (Macromodel, version 
9.8, Schrodinger, LLC, New York, NY, 2010), or Visual 
Molecular Dynamics (VMD) [15]. Analyses were emphasized 
on the N-terminus region containing the first 350 amino acids 
given the length and C-term distance from site of mutation.
Monte Carlo dynamics searching (hybrid MC or via 
enhance MDS sampling) was completed on each model for 
conformational sampling, using methods previously described 
in the literature [16–19]. Briefly, each ABCD1 variant system 
was minimized with relaxed restraints using either Steepest 
Descent or Conjugate Gradient PR, then allowed to undergo 
the MC search criteria, as shown in the literature [16, 17–19]. 
e primary purpose of MC, in this scenario, is examining 
any conformational variability that may occur with different 
mutations in the region near to the mutation and the possible 
effect on DNA binding or processing with the ABCD1.
4. Results
4.1. Structure-Function Studies. For WT versus the variant 
p.K533E, we found the stability of the object from energetic 
calculations for ΔG per amino acid to remain relatively the 
same, such that WT has an object stability of 114.67 kcal/
mol∗Å2. e variant p.K533E causes a net increase in free 
energy of 2.321 kcal/aa∗mol∗Å2, which could be destabilizing 
to the local region [16–18, 20–23]. is object stability was 
positive indicating that some dynamic changes are likely 
with a molecular simulation for conformational sampling. 
us we examined the local residues and determined an 
electrostatic calculation may be useful to explain the change 
in function. e molecular model for the full structure and 
its variant form are given (Figure 3(a)) using our state of the 
art methods, which have been established [16–20, 23–30]. e 
dimeric model is critical for function and shows important 
interactions at the site of mutation that are disrupted by the 
variant mutation.
Local residues within the 12 Å cutoff near the variant site 
(p.K533E) include residues from both monomers. e mon-
omer containing the variant (monomer 1, gray carbons) has 
the following nearby residues with position 533-interactions: 
E471, Q472, I474, I475, E499, Y532, P534, P535, and K624 
(Figure 3(b)). is variant structure (p.Lys533Glu) was ana-
lyzed and more straightforward disruption of the local envi-
ronment was indicated from the positive lysine (+) charge 
flipping to a negative glutamic acid (−) that was quite disrup-
tive to the adjacent charged residues (above). In particular, 
residues K624, E499, and Y532 are placed into different 
N
Figure 2: Family pedigree. Shaded individuals had reported history 
of gait dysfunction. ∗Indicates limited medical history known. e 
proband is marked with an arrow.
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K533, which shows few negatively charged regions and large 
neutral pockets due to the rich hydrophobic residues found 
in the helices mentioned above. e threonine mutation 
seems to change the distribution for the charges and places 
the position for the negative charges further away from each 
other while increasing the size of the neutrally charged regions 
(Figures 4(a) and 4(b)). e p.K533E local region is charged 
to match the positive lysine residue with adjacent glutamic 
acid residues (within 6 Å) (Figure 4(b)). Conversely, residue 
K533 has positive charges that are impacted by residues within 
6 Å, namely E471, Q472, I474, I475, E499, Y532, P534, P535, 
and K624 (Figure 4(a)) [16–18, 20–23]. e variant p.K533E 
does not seem to bear any effect on the dimer itself (Figures 
3 and 4), since the variant is distal to the interface between 
the monomers. However, there is significant disruption in the 
local vicinity where the lysine is natively inserted into a pocket 
with its nearby residues that are oppositely charged and engage 
in H-bonds and salt bridge interactions, which is lost with the 
negative charge from glutamic acid substitution (Figure 3).
5. Discussion
For patients with AMN, options for treatment are currently 
limited. However, recent research with mouse models poses a 
interactions (Figure 3(b)). Local ΔG per amino acid increases 
a net positive value corresponding to unfavorable stability in 
the pocket and longer dynamics would be required to deter-
mine the overall effect but can expected to be destabilizing. 
e K533E residue has interesting interactions with Q472, 
I474, I475, and E499. K533E is in a helix-helix region where 
its charged side chain is positioned outward to oppositely 
charged species; there is also some helix-helix interaction with 
the adjacent helices (Figures 3(b) and 3(c)). e same residues 
are implicated in the variant, but the position is changed for 
several of the residues including P534, P535, and K624 
(Figure 3(c)). is interaction could account for altered func-
tion due to change in dynamic behavior for the local structural 
stability (Figure 3(c)). Electrostatic calculations were com-
pleted for further analysis (Figure 4). In particular, residues 
K624, E499, and Y532 are placed into different interactions 
(Figure 3(b)). Local ΔG per amino acid increases a net positive 
value corresponding to unfavorable stability in the pocket and 
longer dynamics would be required to determine the overall 
effect but can be expected to be destabilizing.
4. 2. Dimer Formation Effects. Mapping electrostatics was 
accomplished using the Poisson–Boltzmann calculation for 
solvation on the entire 745 amino acid structure. e effects 
of the changes were strongly pronounced on electrostatic 
distribution with a +3 KT/E cutoff for both. e WT particle 
(all 745 aa) shows a distinct distribution of charge around 
(A)
(B) (C)
Figure 3: ABCD1 molecular model for full-length human sequence 
for variant p.K533E. (A) Full-length dimeric model for the entire wild 
type (WT) ABCD1 structure shown as ribbon structure with VdW 
sticks for position 533. (B) Zoom-in on the wild-type for the Lys533 
residue from the full-length model to better show the interacting 
residues and dimer interface. Monomer 1 is gray and monomer 2 is 
orange. e residues within interaction distance to K533 are shown 
and yellow dash line is H-bonds and pink dash line is salt bridges. 
(C) Zoom-in on the region around Glu533 variant, showing nearby 
residues and the resulting distortion of the “pocket” around E533 due 
to the charge flipping (+ to −).
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Figure 4:  ABCD1 electrostatic mapping for interaction potential 
for the full-length model for the entire ABCD1 structure with 
electrostatics calculated using Poisson–Boltzman (PB) calculation 
overlaid onto structure. e relevant region is zoomed into showing 
all residues within 12 Å of residue position. (A) Interacting residues 
surrounding the residues are given with PB electrostatics mapped 
onto them. e black labels are for monomer 1 positions of amino 
acids nearby residues and purple label are given for monomer 2 
positions of amino acids nearby to central residues. e electrostatic 
map shows the negative to positive (red to blue) distribution and the 
contours and shape of the protein in this region. (B) Mutant variant 
from ABCD1 model is given with electrostatics overlaid indicating 
changes in charge. e depiction is similar to (A).
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classifying his variant as pathogenic, but the molecular charges 
seem to indicate this region of the protein is significantly per-
turbed from equilibrium (Figure 3(b)). Utilization of the pro-
tein modeling also provided information for incorporation 
into the proband’s larger clinical picture. Additionally, one 
instance of this variant’s pathogenicity is listed in the ALD 
Mutation Database. Combined, this evidence allowed for a 
confident diagnosis of AMN. Our proband had typical symp-
toms of AMN, but the phenotypic variability inherent in 
ABCD1 could result in a different X-ALD presentation for 
other individuals possessing this variant.
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potential solution. In X-ALD patients, the buildup of VLCFAs 
is accompanied by increased levels of radical oxygen species. 
ese radicals drive disease progression, damaging tissue and 
ultimately causing the appearance of neurological symptoms. 
Mice with X-ALD analogues have been successfully treated 
with a mixture of antioxidants, bringing radical levels under 
control and halting this pathogenic process [31]. If later trials 
continue to prove promising, it is possible that our proband 
and other AMN patients could one day be treated in a similar 
manner.
Although our proband presented with a poorly-under-
stood variant in ABCD1, his case did not differ significantly 
from the typical AMN phenotype. Symptoms began in his late 
twenties, which fits neatly in the expected age range of 20 to 
40 years old. AMN typically has spinal cord involvement, 
something that was confirmed by the proband’s MRIs. His leg 
weakness and gait abnormality is characteristic of the disease, 
as is urinary incontinence. Vomiting and nausea are associated 
with adrenal insufficiency, while the proband’s speech and 
mental abnormalities could be associated with cerebral 
changes [3]. Despite this, it must be said that a patient having 
the same ABCD1 variant expressed by our proband could 
present with different symptoms. Pathogenic variants in 
ABCD1 rarely result in predictable phenotypes—even when 
an identical version is possessed by family members [4].
e protein informatics derived from the statistical 
mechanics calculations applied to the molecular modeling for 
the variants versus the wild type gives us clear indication for 
dysfunction of the normal protein behavior at a molecular 
level that would impact the function. For instance, we found 
variant p.K533E causes a net increase in free energy of 
2.321 kcal/aa ∗ mol ∗ Å2, which destabilizes the local region 
within 12 Å of residue K533. Due to the local structural change 
mitigated through backbone residues and secondary-structure 
interaction changes (H-bond network not shown) allow cor-
related motion to propagate throughout the structure further 
frustrating the proper formation of the dimer.
Due to the rarity of our proband’s ABCD1 variant, the 
commercial laboratory was not able to confidently name the 
variant pathogenic. Additionally, logistical challenges and the 
proband’s small family size made family segregation analysis 
impractical. As a result, this process could not be completed 
to help us better understand the significance of his variant. 
ankfully, molecular modeling provided us with another 
opportunity. Protein molecular modeling supported suspi-
cions that this variant would impact protein function in a 
clinically significant way. It was without any suspicion that this 
variant would not have been classified pathogenic given the 
gross alteration to the structure, which was strongly supported 
by the PIP analysis.
6. Conclusion
In conclusion, we report a proband with a rare variant in 
ABCD1, c.1599G>T (p.Lys533Asn). e lack of information 
on this variant prevented the genetic testing company from 
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